Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study.
Thirty-one patients with clinical and laboratory diagnoses of infectious mononucleosis who had had symptoms for seven or fewer days were randomized for intravenous treatment with acyclovir (10 mg/kg) or placebo at 8-hr intervals for seven days in a double-blind trial. Clinical signs and symptoms were registered, and excretion of virus in the saliva as well as antibody responses in sera and saliva were assessed before, during, and at regular intervals in the six months after treatment. Acyclovir significantly (P less than .001), but reversibly, inhibited oropharyngeal shedding of Epstein-Barr virus. The humoral and cellular immune responses, however, did not differ between the two groups; nor did the development of viral latency. There were no significant (P greater than .05) differences in individual clinical symptoms or in laboratory parameters between the two groups; however, when data concerning duration of fever, weight loss, tonsillar swelling, pharyngitis, and self-assessment by the patient were combined, a significant (P less than or equal to .01) effect of treatment with acyclovir was evident.
D000212:Acyclovir / Q000097:blood / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000276:immunology; D036022:Capsid Proteins; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007244:Infectious Mononucleosis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D008297:Male; D011897:Random Allocation; D012463:Saliva / Q000276:immunology / Q000382:microbiology; D013601:T-Lymphocytes / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; C041788:Epstein-Barr viral capsid antigen; D000212:Acyclovir